基石藥業(02616.HK)CS2009臨床研究計劃擴展至美國
基石藥業(02616.HK)公布,其自研的靶向PD-1、VEGFA和CTLA-4新型三特異性抗體產品「CS2009」,所進行的全球多中心I/II期臨床研究正在澳洲及中國積極招募患者,有計劃擴展至美國進行II期入組,預計今年底前試驗入組患者數將突破100例,Ib期/II期研究預計今年下半年啟動。
公司又指,目前CS2009在所有評估劑量水平上展現良好耐受性,藥代動力學特徵支持每三周給藥一次,並在低劑量組的「冷腫瘤」及PD-(L)1經治患者中觀察到抗腫瘤活性,Ia期臨床數據預計將於今年第四季發布。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.